IMMIX BIOPHARMA INC
IMMXNASDAQTrading Snapshot
- Day Range
- $10.48 – $10.66
- 52-Week Range
- $1.99 – $15.10
- Volume
- $1.73B
- Avg Volume
- $2.26B
- Shares Outstanding
- 54.4M
- Next Earnings
- Oct 27, 2026
Fundamentals Snapshot
- Annual Revenue
- $42M
- Last Q Revenue
- $10M
- P/E Ratio
- -12.3
- P/S Ratio
- 0.0x
- EPS (TTM)
- $-0.63
- Dividend Yield
- 0.00%
- Dilution (1yr)
- +39.0%
Why Investors Own IMMX
- ✓High-growth profile — revenue up +17.6% YoY with expanding US Equity exposure.
- ✓Healthy economics — 67% gross margin and 5% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
IMMIX BIOPHARMA INC
IMMX
StockOtter · stockotter.spaceAbout IMMIX BIOPHARMA INC
Immix Biopharma, Inc. is a clinical-stage biotechnology firm dedicated to creating a range of tissue-specific therapies. Operating in both the United States and Australia, their primary focus areas are oncology (cancer) and inflammatory diseases. Their product pipeline includes IMX-110, which is currently undergoing Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and various solid tumors. They are also developing IMX-111, a targeted biologic agent for colorectal cancers, and IMX-120, another tissue-specific biologic designed to address ulcerative colitis and severe Crohn's disease. In a strategic move, the company has forged a clinical collaboration and supply agreement with BeiGene Ltd. This partnership aims to conduct a Phase 1b combination clinical trial, evaluating IMX-110 in conjunction with BeiGene's anti-PD-1 drug, Tislelizumab, for solid tumor indications. Founded in 2012, Immix Biopharma maintains its headquarters in Los Angeles, California.
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Analyst Ratings
ⓘLatest News & Updates
Immix Biopharma (NASDAQ:IMMX) Stock Jumps 4.1% – Should You Buy?
Shares of Immix Biopharma, Inc. (NASDAQ: IMMX - Get Free Report) rose 4.1% during trading on Monday. The stock traded as high as $11.37 and last traded at $11.4250. 314,931 shares changed hands during mid-day trading, a
Immix Biopharma, Inc. (IMMX) Shareholder/Analyst Call Transcript
Immix Biopharma, Inc. (IMMX) Shareholder/Analyst Call Transcript
Immix Biopharma Announces Pricing of $125 Million Underwritten Offering of Common Stock
LOS ANGELES, Sept. 29, 2026 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“ImmixBio”, “Company”, “we” or “us” or “IMMX”), a global leader in relapsed/refractory AL Amyloidosis, today announced the pricing of an underwritten
Immix Biopharma Announces 89% Complete Response Rate at Interim Update Across All NEXICART-2 Patients, with MRD-Negativity Indicating Potential to Reach up to 98% Complete Response Rate, Supporting Potential Best-in-Class Therapy for Relapsed/Refractory AL Amyloidosis
– 100% (25/25) of new patients are either in complete response (CR) or MRD-negative (21/25 are in CR; remaining 4/25 are MRD-negative) –
Immix Biopharma (NASDAQ:IMMX) Reaches New 12-Month High – Still a Buy?
Immix Biopharma, Inc. (NASDAQ: IMMX - Get Free Report)'s stock price hit a new 52-week high during mid-day trading on Tuesday. The company traded as high as $13.80 and last traded at $13.61, with a volume of 1414936 shar
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Immix Biopharma, Inc. - IMMX
NEW YORK, Aug. 13, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Immix Biopharma, Inc. ("Immix" or the "Company") (NASDAQ: IMMX). Such investors are advised to contact Danielle Pey